New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments.

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...